[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"shock-cardiogenic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:shock-cardiogenic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,69,99,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100599494","digital-out-of-hospital-management-on-clinical-outcomes-in-patients-with-early-cardiogenic-shock-100599494",false,"NCT07085221","Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock","Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock: a Multi-center, Randomized Controlled Clinical Trial","DIGI-CS","Inclusion Criteria\n\n1. Age ≥ 18 years old;\n2. The patient meets the diagnosis of early-stage cardiogenic shock, with SCAI stage A, B, or C during hospitalization; (1) SCAI stage A:\n\nWithout signs of shock and meeting one of the following criteria:\n\n1. Combined with extensive myocardial infarction, diagnosed as widespread anterior wall myocardial infarction based on ST-segment elevation in ECG leads (V1-V5, aVL, I leads), inferior wall combined with right ventricular (II, III, aVF, V3R-V5R leads) and\u002For posterior wall myocardial infarction (V7-V9 leads), or recurrent myocardial infarction within 28 days.\n2. Concurrent acute heart failure or acute exacerbation of chronic heart failure. (2) SCAI stage B-C (meeting the following conditions)\n\n1\\) 60 \\\u003C SBP \\\u003C 90 mmHg or mean arterial blood pressure 50 \\\u003C MAP \\\u003C 60 mmHg or a decrease of \\> 30 mmHg from baseline lasting 30 minutes; or SBP ≥ 90 mmHg but heart rate \u002FSBP \\> 1 lasting \\> 30 minutes.\n\n2\\) The highest arterial blood lactate during hospitalization \\\u003C 5 mmol\u002FL. 3. Stable clinical symptoms at discharge, defined as:\n\n1. SBP ≥ 90 mmHg when vasoactive drugs are not used;\n2. No signs and symptoms of shock. 4. Understand and be willing to sign the informed consent, and be willing to follow the treatment and visit plan required by the protocol.\n\nExclusion Criteria\n\n1. Unable to use a smartphone for out-of-hospital management despite training\n2. The reasons for discharge were treatment withdrawal and transfer to another hospital for continued therapy\n3. Previous or current hospital admission due to cardiac arrest\n4. Refractory cardiogenic shock\n5. Refractory Heart Failure (ACC\u002FAHA guidelines Stage D heart Failure)\n6. Left ventricular ejection fraction \\\u003C 30%\n7. (Estimated) glomerular filtration rate \\\u003C 25 ml\u002Fmin or on dialysis\n8. Severe hepatic insufficiency (Child-Pugh class C)\n9. Severe chronic obstructive pulmonary disease (confirmed by pulmonary function tests, or requiring long-term home oxygen therapy or long-term use of corticosteroids)\n10. History of cardiac surgery\n11. Pregnant or lactating women\n12. Combined with malignant tumors and other serious diseases, the expected life span is less than 1 year\n13. Neuropsychiatric disorders, unable to cooperate with management;\n14. Participation in other clinical trials within the past year;\n15. Other circumstances considered to be inappropriate for this study by the investigator.","ALL","18 Years",{"count":20,"type":21},472,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical study was a multi-center, open-label, randomized controlled clinical trial. A total of 472 patients with early-stage cardiogenic shock were recruited and randomly divided into the experimental group and the control group, with 236 cases in each group. The HeartMed-HF digital out-of-hospital management was used to manage the patients in the experimental group, while the patients in the control group were managed according to the discharge guidance. The primary endpoints were 1-year all-cause mortality and unplanned readmission after randomization (excluding emergency department visits). Secondary endpoints (at 3 months, 6 months, and 12 months post-randomization) were: all-cause mortality, rehospitalization for HF, recurrent MI, ischemia-driven repeat revascularization, stroke, BARC 3-5 grade major bleeding, unplanned formal rehospitalization, types of GDMT medications or GDMT target dose achievement rate.",[27,28],"Shock, Cardiogenic","Shock","RECRUITING","2026-06-15",{"date":32,"type":33},"2026-06-17","ACTUAL",{"date":35,"type":33},"2025-07-26",{"date":37,"type":21},"2028-12-31",{"name":39,"class":40},"Renmin Hospital of Wuhan University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100459843","phase-4-capital-doremi-2-inotrope-versus-placebo-therapy-for-cardiogenic-shock-100459843","NCT05267886","CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock","DOREMI-2","Inclusion Criteria:\n\n* Adult patients ≥ 18 years of age admitted to an intensive care unit\n* SCAI class C or D cardiogenic shock\n\nExclusion Criteria:\n\n* Unwilling or unable to obtain informed consent by the participant or substitute decision maker\n* Patients who are currently pregnant or breast-feeding\n* Patients presenting with an out-of-hospital cardiac arrest (OHCA)\n* Administration of milrinone or dobutamine in the 24 hours preceding anticipated randomization\n* Severe obstructive valvular lesions, including aortic stenosis and\u002For mitral stenosis\n* Dynamic left ventricular outflow tract obstruction",{"count":50,"type":21},346,[52],"PHASE4","The investigators are interested in determining if there is a meaningful benefit from the use of medications purported to increase the pumping function of the heart (i.e. inotropes) among critically ill patients admitted to the Cardiac Intensive Care Unit (CICU). To do this, the investigators will conduct a multi-centre, double blind, randomized control trial with patients who are deemed to require these medications by their treating physician to one of the two most commonly used agents in Canada (Milrinone or Dobutamine) or placebo. Each patient will be closely monitored by their healthcare team. The dose of medication will be adjusted according to each patients' clinical status. After 12 hours, the participants will move to open label treatment and any continued use of inotropes will be at the discretion of their treating physician.",[27],[56,57,58],"cardiogenic","shock","inotrope","2026-04-27",{"date":61,"type":33},"2026-05-01",{"date":63,"type":33},"2022-03-05",{"date":65,"type":21},"2026-12",{"name":67,"class":40},"Ottawa Heart Institute Research Corporation",3,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100580086","phase-1-invobenitug-also-known-as-procizumab-pcz-ak1967-in-critical-cardiovascular-care-100580086","NCT06832722","Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care","Multi-center, Randomized, Placebo-controlled, Double-blind Phase 1b\u002F2a Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Invobenitug Also Knows as Procizumab (PCZ; AK1967) in Patients With Cardiogenic Shock and Elevated Circulating Dipeptidyl Peptidase 3 (cDPP3) Concentrations","PROCARD 2a","Inclusion Criteria:\n\n1. Signed informed consent.\n2. Diagnosis of CS based on the following entry criteria:\n\n   1. Need for ongoing vasopressors and\u002For inotropes to maintain a MAP ≥ 65 mmHg or SBP ≥ 90 mmHg\n   2. Lactate ≥ 2.0 mmol\u002FL\n   3. High cDPP3 concentration ≥ 30 ng\u002FmL\n3. Etiology of CS must be one of the following: ACS, septic or adHF origin\n\n   Exclusion Criteria:\n4. Patients who will be receiving vasopressors and\u002For inotropes for more than 16 hours prior to receiving the IMP.\n5. Patients being longer than 24 hours in the ICU at the time of randomization.\n6. Patients below the age of 18 or above 80 years.\n7. Patients receiving Ang II and\u002For levosimendan.\n8. Patients with known allergies or hypersensitivity to the IMP or its excipients or any related medication.\n9. Stroke or transient ischemic attack within the last 3 months.\n10. SCAI Shock Stage E.\n11. Reduced life expectancy of less than 6 months due to comorbidities (prior to shock onset).\n12. Very severe frailty, or moribund condition or presence of clinical circumstances indicating imminent death.\n13. Only for Part 1: Patients on cannula-based MCS (including VV and VA-ECMO, impella or left ventricular assist device of any type (excluding IABP)) or on renal replacement therapy. Patients who are treated by impella and\u002For ECMO but have no evidence of hemolysis during screening can be enrolled in the trial.\n14. Patients exceeding a maximum body weight of 120 kg.\n15. CPR lasting more than 15 minutes and\u002For the patient is not conscious at randomization.\n16. Primary hypertrophic or restrictive cardiomyopathy or congenital heart disease or systemic illness known to be associated with infiltrative heart disease.\n17. Pericardial constriction\n18. Sustained SBP \\> 120 mmHg during the hour prior to randomization.\n19. Known severe chronic liver disease (Model for End-Stage Liver Disease (MELD) Score \\>30), known severe chronic pulmonary disease (including COPD classification GOLD4 and\u002For chronic oxygen therapy and\u002For restrictive chronic pulmonary disease and\u002For severe interstitial lung disease), known severe thyroid disease, known CKD with eGFR \\\u003C 20 ml\u002Fmin\u002F1.73 m2 or chronic dialysis.\n20. Patients with untreated sepsis.\n21. Patients with valvular heart diseases as the primary cause of cardiogenic shock.\n22. Other known causes of shock, namely\n\n    1. Hypovolemia\n    2. Hemorrhage\n    3. Anaphylaxis\n    4. Intoxication (e.g., drug-induced shock)\n    5. Dynamic left ventricular outflow tract obstruction\n    6. Isolated right heart failure, including cardiac tamponade and\u002For pulmonary embolism\n    7. Known mechanical complications due to myocardial infarction, including papillary muscle rupture, ventricular septal rupture, free wall rupture\n    8. Inappropriate pacing or shock resulting from ICD malfunction\n23. Patients who have severe immune suppression such as recent (\\\u003C3 months) chemotherapy and\u002For severe neutropenia (neutrophil count \\\u003C500 cells\u002Fmm3) and\u002For chronic high glucocorticoid dose (≥0.5 mg\u002Fkg per day of prednisone equivalent) and\u002For recent (\\\u003C3 months) organ transplantation\n24. Patients who have undergone any form of surgery in the last 7 days, except 1) minor surgeries such as cosmetic surgeries, skin surgery, dental surgery and impella implantation 2) surgery for peritonitis with adequate source control, which are allowed.\n25. Women who are pregnant or breastfeeding.\n26. Patients who are currently enrolled in another clinical trial, or who have participated in such trials within one month prior to randomization","80 Years",{"count":79,"type":21},130,[81,82],"PHASE1","PHASE2","The objective of this Phase 1b trial is to evaluate the safety and tolerability of procizumab, a monoclonal antibody under development for the treatment of cardiogenic shock (CS). CS is a life-threatening hypoperfusion of vital organs that frequently results in death. In addition to safety and tolerability, pharmacokinetics and pharmacodynamics of procizumab are evaluated to define the optimum phase 2 dose (P2D) of procizumab.",[27],[86,87],"Cardiogenic shock","Procizumab","2026-04-21",{"date":90,"type":33},"2026-04-23",{"date":92,"type":33},"2025-07-13",{"date":94,"type":21},"2026-12-01",{"name":96,"class":97},"4TEEN4 Pharmaceuticals GmbH","INDUSTRY",20,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":117,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100587932","phase-4-ciprofols-impact-on-oxygenator-function-in-extracorporeal-membrane-oxygenation-ecmo-patients-100587932","NCT06934811","Ciprofol's Impact on Oxygenator Function in Extracorporeal Membrane Oxygenation (ECMO) Patients","Evaluating the Impact of Ciprofol on Oxygenator Performance in Patients Undergoing Extracorporeal Membrane Oxygenation: A Single-Center Randomized Controlled Trial (CIP-OXY Study)","CIP-OXY","1. Inclusion Criteria:\n\n   * Receiving ECMO therapy with an anticipated duration exceeding 72 hours;\n   * Requiring invasive mechanical ventilation;\n   * Requiring sedation and analgesia treatment.\n2. Exclusion Criteria:\n\n   * BMI \\>45 kg\u002Fm²;\n   * Age \\\u003C18 years;\n   * Severe hepatic (Child-Pugh Class C) or renal failure (eGFR \\\u003C15 mL\u002Fmin\u002F1.73m²);\n   * History of severe psychiatric disorders;\n   * Pregnancy;\n   * Refusal to sign informed consent;\n   * Contraindications to midazolam and propofol use.","75 Years",{"count":109,"type":21},30,[52],"This study evaluates the safety and effectiveness of Ciprofol, a new sedative, in critically ill patients receiving Extracorporeal Membrane Oxygenation (ECMO), a life-support system for heart or lung failure. The investigation aims to:\n\nAssess how Ciprofol affects the oxygenator, a critical ECMO component responsible for adding oxygen to blood.\n\nCompare the safety of Ciprofol to midazolam, a commonly used sedative. Eligibility Criteria Adults aged 18 years or older. Patients receiving ECMO and mechanical ventilation for over 72 hours. Individuals requiring sedation for medical procedures. Study Protocol\n\nParticipants will be randomly assigned to one of two groups:\n\nCiprofol Group: Initial sedation dose of 0.1 mg\u002Fkg, adjusted as needed. Midazolam Group: Initial sedation dose of 0.05 mg\u002Fkg, adjusted as needed. Both groups will receive pain management with remifentanil. Sedation levels will be adjusted daily by the clinical team to ensure patient safety and comfort.\n\nOutcome Measures Primary: Oxygenator performance (oxygen and carbon dioxide levels) on Days 3 and 7.\n\nSecondary: Changes in blood triglyceride and clotting marker (D-dimer) levels, oxygenator lifespan before replacement, and safety outcomes such as low blood pressure, respiratory issues, or allergic reactions.\n\nSignificance ECMO patients often require prolonged sedation, but current sedatives like midazolam may contribute to oxygenator damage. Ciprofol's potential for faster recovery and fewer side effects could improve sedation practices and device longevity in this high-risk population.",[113,114,115,116,27],"ECMO Treatment","ARDS (Acute Respiratory Distress Syndrome)","ECMO and Acute MI","Respiratory Failure Patients Treated With ECMO",[118,119,120,121,122,123,124],"Ciprofol","ECMO","Oxygenator function","Sedative","Randomized Controlled Trial","Midazolam","Oxygenator thrombosis","NOT_YET_RECRUITING","2025-04-12",{"date":128,"type":33},"2025-04-18",{"date":130,"type":21},"2025-05-01",{"date":132,"type":21},"2026-12-31",{"name":134,"class":40},"First Affiliated Hospital of Wannan Medical College",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":143,"maxAge":77,"enrollmentInfo":144,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":41},"100574955","ecmo-left-ventricle-unloading-strategy-100574955","NCT06766006","ECMO LEft Ventricle UNloading Strategy","A Multicentric Left Ventricular Venting Strategy Comparison in Patients Receiving Venoarterial Extracorporeal Life Support","ECMOLENS","Inclusion Criteria:\n\n* All patients undergoing VA ECLS will be enrolled.\n\nExclusion Criteria:\n\n* Patients without VA ECMO will not be considered","1 Day",{"count":145,"type":21},500,"OBSERVATIONAL","The present study is an International multicentric prospective observational cohort study. This will be an international research campaign to prospectively collect and analyze clinical data of all VA ECLS patients admitted to participating ICUs with a focus on LV venting modalities. The aims of the study are:\n\n* To investigate the meaning of LV overload during veno-arterial (VA) extracorporeal life support;\n* To extensively describe the left ventricular (LV) unloading strategy during VA extracorporeal life support in a large prospective international cohort.\n* To compare different strategies to unload the left ventricular in terms of efficacy and outcomes;",[27,149,150],"Cardiac Arrest","Extracorporeal Membrane Oxygenation Complication",[152,153,86,149,154],"Extracorporeal Membrane Oxygenation","Left ventricle unloading","Mechanical Circulatory Supports","2025-01-03",{"date":157,"type":33},"2025-01-09",{"date":159,"type":33},"2024-04-01",{"date":161,"type":21},"2026-04-01",{"name":163,"class":40},"Maastricht University Medical Center"]